Agenus Inc. (AGEN) Q2 2026 Earnings: Revenue $35M (+34.4%)
AGEN — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop
Agenus narrowed its Q2 2026 net loss to $0.6M from $28.0M as costs fell 45% after the Zydus plant sale, but most revenue is non-cash royalties, cash was $18.7M, and the going-concern warning remains.
Revenue
$35M
+34.4% YoY
Net income
-$604K
+97.8% YoY
Diluted EPS
$-0.01
+99.0% YoY
Operating margin
32.7%
This period vs a year ago
Same period last year
This period
Revenue▲+34.4%
≈$26M
$35M
Year-ago figures (≈) are worked out from the growth rate the company reported. Each row has its own scale.
Overview
Agenus reported a second-quarter 2026 net loss of just $0.6 million, compared with $28.0 million a year earlier. The company did not start making money from its cancer drugs. Two things narrowed the loss: operating costs fell 45% after it sold its manufacturing plants to Zydus Lifesciences in January, and a non-cash accounting revenue line grew. That line is GSK vaccine royalties that Agenus sold to an investor years ago, so none of the cash reaches Agenus. The cash picture is still tight. Agenus ended June with $18.7 million in cash, and the 10-Q still carries a "substantial doubt" going-concern warning. An $85 million private placement in July funds operations only into the third quarter of 2027. Almost everything after that depends on investors exercising warrants tied to the company's planned Phase 3 colon-cancer trial, ROBBIN.
At a glance
$6.4 million of product revenue from paid early-access programs for its drug combination BOT+BAL (up from $4.6 million in Q1). This is the only revenue line that brings in cash.
$23.2 million of operating costs, down from $42.4 million. Most of the cut came from selling the manufacturing sites and their staff to Zydus.
Cash into Q3 2027 only. That estimate counts the July raise but no warrant money, and the going-concern warning is still in place.
Q2 2026 results
Metric
Q2 2026
Q2 2025
YoY Change
Total revenue
$34.5M
$25.7M
+34.4%
of which: non-cash royalty revenue
$28.1M
$24.8M
+13.3%
Read 0 community reports on Agenus Inc., or write your own.Write a report
of which: pre-commercial product revenue (BOT+BAL)
$6.4M
—
new
Research & development expense
$14.8M
$26.7M
-44.7%
General & administrative expense
$8.5M
$15.5M
-45.4%
Operating income (loss)
$11.3M
-$16.7M
improved
Operating margin
32.7%
-65.0%
+97.7 pts
Interest expense, net
$15.2M
$13.3M
+14.7%
Net loss attributable to common stockholders
-$0.6M
-$28.0M
loss 97.8% smaller
Diluted EPS
-$0.01
-$1.00
+$0.99
Weighted average shares (basic)
41.3M
28.1M
+47.0%
Cash & equivalents (period-end)
$18.7M
$3.0M (Dec 31, 2025)
—
Source: Form 10-Q for the quarter ended June 30, 2026. Operating margin is operating income divided by total revenue, i.e. the share of revenue left after running costs, before interest.
For the first six months, Agenus reported net income of $38.6 million, compared with a $56.4 million loss a year earlier. That profit comes from a one-time $40.4 million accounting gain on the Zydus plant sale. Without the gain, the half-year would have been roughly break-even to slightly loss-making, for the same reasons as Q2.
Where the revenue comes from, and why most of it isn't cash
Agenus makes QS-21, an ingredient that makes vaccines work harder (an "adjuvant"), and GSK uses it in its vaccines. Years ago Agenus sold its future QS-21 royalties to HealthCare Royalty (HCR) for $190 million upfront. Under the accounting rules, Agenus still books those royalties as revenue ($28.1 million this quarter), but GSK pays them straight to HCR. The 10-Q says plainly that this revenue "does not provide cash to the company." The same deal creates most of the $15.2 million interest expense, which is also mostly non-cash. The filing says interest rose because of "increased sales forecasts of GSK's vaccines containing our STIMULON QS-21 adjuvant." Higher GSK sales mean HCR recovers more, so a larger implied interest charge gets booked.
The only operating cash coming in is the $6.4 million of pre-commercial product revenue. BOT+BAL (botensilimab, an antibody that blocks the CTLA-4 immune brake, plus balstilimab, which blocks PD-1) is not approved anywhere. Patients get it through France's compassionate-access program (AAC), where the national health system pays for it, and through physician-requested paid named-patient programs in other countries. Six-month product revenue was $11.0 million.
If you leave out the royalty pass-through, Q2 looks like this: about $6.4 million of cash-type revenue against $23.2 million of operating costs, an operating loss of roughly $17 million.
What the headline numbers hide
The small loss is mostly accounting, not a turnaround. Non-cash royalty revenue ($28.1M) far exceeds the non-cash interest it generates. Operating cash flow for the half-year was -$67.1 million, worse than -$45.8 million a year earlier, even though the income statement showed a $38.6 million profit. Part of that gap is working capital: Agenus paid down $24.0 million of accounts payable (unpaid supplier bills fell from $83.0M to $59.0M), and receivables grew $12.9 million as access-program billings came in. Management expects to collect those receivables in Q3.
The going-concern warning is still there. The notes say "substantial doubt exists about our ability to continue as a going concern for at least one year" after the statements were issued. The stated reason is that the financing and strategic deals it needs are "not entirely within our control."
Cash runway. Cash was $18.7 million at June 30. Another $7.6 million sits in an escrow account from the Zydus deal, released under set conditions over 12 months. Management says cash plus the July placement's net proceeds covers operations "into the third quarter of 2027," assuming no warrant exercise. That plan already counts on access-program revenue continuing.
Heavy dilution. Shares outstanding went from 35.3 million at year-end to 42.6 million at June 30, through the $16.0 million Zydus share purchase at $7.50, at-the-market sales, and shares issued for services and the CEO's payroll. The July placement then added about 23.0 million shares and pre-funded warrants at an effective $3.69 per unit, plus warrants on 54.9 million more shares: 21.1 million Series A at $4.02 and 33.8 million Series B at $5.03. If every warrant is exercised, the share count would pass roughly 120 million, close to three times the June figure.
The warrants have deadlines tied to trial milestones. Series A warrants expire 30 days after Agenus announces that 60 patients have been dosed in ROBBIN. Series B warrants expire 30 days after it publishes pathologic-response data on 50 BOT+BAL patients in ROBBIN, or when the holder's Series A expires unexercised. Holders only exercise if the share price is above $4.02 / $5.03 at those points. The $255 million of "potential" money therefore depends on the stock price, not on anything Agenus can guarantee.
The balance sheet is still upside down. Stockholders' deficit was $205.9 million, meaning liabilities exceed assets. Of the liabilities, $249.5 million comes from the two royalty-sale deals (HCR and Ligand). Those are repaid out of future royalty and milestone payments, not from Agenus's operating cash. Actual short-term debt was $30.1 million. After the quarter, Agenus extended the maturity of the largest piece, a $24.75 million note, to November 30, 2029, at 13% interest paid half in stock. It also pushed $5.09 million of 2015 notes out to January 18, 2027.
The Zydus deal isn't all cash. Agenus received $91.0 million at the January closing: $75.0 million for the Emeryville and Berkeley plants and a $16.0 million share purchase, before $5.8 million of transaction costs and the $7.5 million escrow. A further $40.0 million "contract asset" on the balance sheet is prepaid clinical drug supply from Zydus that will be booked as R&D as it is delivered, so it isn't available cash. Zydus also got BOT+BAL rights in India and Sri Lanka, with royalties to Agenus.
Takeaway: A near-zero quarterly loss makes Agenus look close to self-sustaining, but it isn't. Strip out royalties that go straight to a creditor and the business lost about $17 million from operations this quarter. It burned $67 million of operating cash in the half and has funding only into Q3 2027. Its long-term financing depends on warrant holders choosing to put in up to $255 million as ROBBIN hits dosing and data milestones.
Strategy shift: everything on ROBBIN
In July, Agenus narrowed its development spending to one bet: ROBBIN, a planned global Phase 3 trial in about 850 patients with high-risk Stage II/III microsatellite-stable (MSS) colon cancer. MSS is the roughly 85% of early colorectal cancers that usually don't respond to immunotherapy. Patients would get a short course of BOT+BAL before surgery, compared with surgery plus standard care, and the main measure is event-free survival (time without the cancer coming back or worsening). Agenus says the design reflects FDA feedback. The rationale comes from two independent investigator studies, NEST and UNICORN. Among 38 patients treated with BOT+BAL before surgery, about 30% had no viable tumor left at surgery, about 40% had 10% or less remaining, and no recurrences had been reported at the data cutoffs. Those are small, non-randomized studies. ROBBIN is meant to test whether the effect holds up in a controlled trial.
To pay for the focus, Agenus stopped funding BATTMAN, a Phase 3 trial run by the Canadian Cancer Trials Group in late-stage metastatic MSS colorectal cancer, and the group then terminated the study. Agenus says the decision was "not driven by enrollment performance, efficacy or safety findings." In the metastatic setting, an update from the 123-patient Phase 1b cohort (refractory MSS colorectal cancer without active liver metastases) showed median overall survival of 21.2 months and 33% of patients alive at three years.
The quarter also removed two legal overhangs: the SEC closed its investigation of the company, and the related securities class action was dismissed.
Outlook
Management's stated milestones:
Longer-term follow-up manuscripts from NEST and UNICORN in the second half of 2026
Investigator-sponsored BOT+BAL presentations at ESMO 2026
ROBBIN initiation and first patient dosing in Q1 2027
Our read: the next 12 months are about cash timing more than clinical data. First dosing in Q1 2027 and funding that lasts "into" Q3 2027 leave little room. Enrolling 60 patients, the point that sets off the Series A deadline, has to happen fast enough, and at a high enough share price, for warrant holders to put money in before the runway ends. If enrollment is slow or the stock trades below $4.02, Agenus would need another raise or a partnership. Management says it is in "active discussions" about partnerships, which likely means more dilution. For now, the lines to watch each quarter are product revenue from access programs (the only real cash income, growing from $4.6M to $6.4M) and operating cash burn.